{
    "clinical_study": {
        "@rank": "143053", 
        "acronym": "CPP1-05", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 with 0.5 units of CPP", 
                "arm_group_type": "Experimental", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)"
            }, 
            {
                "arm_group_label": "Cohort 1 with 1 unit of LSP", 
                "arm_group_type": "Active Comparator", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)"
            }, 
            {
                "arm_group_label": "Cohort 2 with 1 unit of CPP", 
                "arm_group_type": "Experimental", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)"
            }, 
            {
                "arm_group_label": "Cohort 2 with 1 unit of LSP", 
                "arm_group_type": "Active Comparator", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)"
            }, 
            {
                "arm_group_label": "Cohort 3 with 2 units of CPP", 
                "arm_group_type": "Experimental", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)"
            }, 
            {
                "arm_group_label": "Cohort 3 with 1 unit of LSP", 
                "arm_group_type": "Active Comparator", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)"
            }, 
            {
                "arm_group_label": "Cohort 4 with 3 units of CPP", 
                "arm_group_type": "Experimental", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)"
            }, 
            {
                "arm_group_label": "Cohort 4 with 1 unit of LSP", 
                "arm_group_type": "Active Comparator", 
                "description": "A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety of intravenous (IV) infusion of dimethyl sulfoxide\n      (DMSO) cryopreserved platelets (CPP) in participants with World Health Organization (WHO)\n      Grade 2 bleed in spite of receiving a transfusion of liquid stored platelets (LSP) in the\n      past 48 hours by collecting adverse events (AEs) and by evaluating coagulation-related\n      parameters to assess the evidence of any thrombotic events after CPP or LSP transfusion.\n\n      Descriptive statistics will be used to present the study data."
        }, 
        "brief_title": "Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, at least 18 years of age.\n\n          -  Blood type A or O.\n\n          -  Ability to comprehend the study procedures and signed informed consent.\n\n          -  If pre-menopausal female, must have a negative serum pregnancy test, and, if of child\n             bearing potential, must be using an acceptable method of contraception.\n\n          -  Diagnosed with any the following: acute leukemia, chronic leukemia, myelodysplasia,\n             aplasia, hematopoietic or non-hematopoietic solid tumor, or therapy (chemotherapy or\n             radiation) induced bone marrow aplasia or hypoplasia. Either autologous or allogeneic\n             bone marrow transplant or peripheral or cord blood stem cell recipients may be\n             enrolled.\n\n          -  World Health Organization (WHO) grade 2 or greater bleeding.\n\n          -  Liquid stored platelets (LSP) transfusion within the previous 48 hours.\n\n        Exclusion Criteria:\n\n          -  Splenomegaly (for the purposes of this study, it is defined as a palpable spleen 5 cm\n             below the costal margin or >18 cm in the largest dimension by ultrasound).\n\n          -  Blood type other than A or O.\n\n          -  Acute or chronic disseminated intravascular coagulation (DIC) as evidence by D-dimers\n             greater than 8 \u00b5g/mL and fibrinogen less than 100 mg (0.1 g)/dL. Both criteria must\n             be met. If data are in the medical record for fibrin degradation products (FDPs),\n             then FDP must be \u2264 40 \u00b5g/mL (FDP >40 \u00b5g/mL is indicative of DIC).\n\n          -  Prothrombin time (PT) or activated partial thromboplastin time (aPTT) > 1.3 times the\n             upper limit of normal for the laboratory.\n\n          -  History of major operative procedures that required general anesthesia in the past 2\n             weeks.\n\n          -  History of any prior major unprovoked thrombotic events and/or known inherited\n             disorder of coagulation or platelet function (by history) (not to include clots in\n             catheters, etc).\n\n          -  A history or diagnosis of immune thrombocytopenia, thrombotic thrombocytopenic\n             purpura, or hemolytic uremic syndrome.\n\n          -  Clinically significant chronic renal (creatinine >1.8 mg/dL) or hepatic dysfunction\n             (PT >1.3 x the upper limit of normal for the laboratory).\n\n          -  Females who are breastfeeding.\n\n          -  Veno-occlusive disease or possible veno-occlusive disease.\n\n          -  Receiving active, inpatient treatment with anti-platelet drugs and/or full\n             anti-coagulation therapy. Note: a heparin flush may be given daily and before and\n             after blood draws to patients with a central line to keep the line patent.\n\n          -  Subject previously enrolled in this study and received a study transfusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078284", 
            "org_study_id": "S-12-04"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 with 0.5 units of CPP", 
                    "Cohort 2 with 1 unit of CPP", 
                    "Cohort 3 with 2 units of CPP", 
                    "Cohort 4 with 3 units of CPP"
                ], 
                "description": "One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at \u2264 -65\u00b0C.", 
                "intervention_name": "CPP", 
                "intervention_type": "Biological", 
                "other_name": "dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1 with 1 unit of LSP", 
                    "Cohort 2 with 1 unit of LSP", 
                    "Cohort 3 with 1 unit of LSP", 
                    "Cohort 4 with 1 unit of LSP"
                ], 
                "intervention_name": "LSP", 
                "intervention_type": "Biological", 
                "other_name": "liquid stored platelets (LSP)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dimethyl Sulfoxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "platelet transfusion", 
        "lastchanged_date": "February 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sjslichter@psbc.org", 
                    "last_name": "Sherrill J Slichter, MD", 
                    "phone": "206-292-6541"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Puget Sound Blood Center"
                }, 
                "investigator": {
                    "last_name": "Sherrill J Slichter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bldbuddy@u.washington.edu", 
                    "last_name": "Terry B Gernsheimer, MD", 
                    "phone": "206-543-3360"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "University of Washington, Division of Hematology"
                }, 
                "investigator": {
                    "last_name": "Terry B Gernsheimer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding Not Responding to Standard Platelet Therapy", 
        "overall_contact": {
            "email": "sjslichter@psbc.org", 
            "last_name": "Sherrill J Slichter, MD", 
            "phone": "206-292-6541"
        }, 
        "overall_contact_backup": {
            "email": "bldbuddy@u.washington.edu", 
            "last_name": "Terry B Gernsheimer, MD", 
            "phone": "206-543-3360"
        }, 
        "overall_official": [
            {
                "affiliation": "Puget Sound Blood Center", 
                "last_name": "Sherrill J Slichter, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Washington, Division of Hematology", 
                "last_name": "Terry B Gernsheimer, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number and percentage of adverse events", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with clinical laboratory findings. Evaluations to include are chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit).", 
                "measure": "Clinical laboratory findings", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with physical examination findings.", 
                "measure": "Physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with electrocardiogram (ECG) findings", 
                "measure": "Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with vital sign findings", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with any signs or symptoms of thrombotic events.", 
                "measure": "Thrombotic events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }, 
            {
                "description": "Number and percentage of participants with pre and post CPP transfusion coagulation findings. These include fibrinogen, D-dimer, prothrombin fragments 1 + 2, thrombin-anti-thrombin (TAT), anti-thrombin (AT), prothrombin time (PT), and activated partial thromboplastin time (aPTT) findings", 
                "measure": "Pre and post CPP transfusion coagulation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 days after transfusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}